Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
Inhibikase Therapeutics, Inc. (IKT) had Pre-Tax Income of $-19.59M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-19.59M |
|
-- |
|
-- |
|
$21.05M |
|
$-21.05M |
|
$1.46M |
|
|
Pre-Tax Income |
$-19.59M |
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-19.59M |
|
$-21.05M |
|
$-21.05M |
|
174.57M |
|
174.57M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$162.34M |
|
-- |
|
$1.24M |
|
$163.59M |
|
$10.26M |
|
-- |
|
-- |
|
$10.26M |
|
$153.33M |
|
$153.33M |
|
$153.33M |
|
132.03M |
|
| Cash Flow Statement Financials | |
$-24.50M |
|
$-86.39M |
|
$2.88M |
|
$139.22M |
|
$31.21M |
|
$-108.01M |
|
$10.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-24.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.78% |
|
-12.78% |
|
-11.98% |
|
-12.78% |
|
$1.16 |
|
$-0.14 |
|
$-0.14 |
|